Arcutis Biotherapeutics, Inc.
ARQT
$20.69
-$0.55-2.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -17.34% | 28.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.61% | 30.52% | |||
| Cost of Revenue | -16.29% | 34.58% | |||
| Gross Profit | -18.84% | 30.13% | |||
| SG&A Expenses | -6.21% | 26.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.03% | 22.52% | |||
| Operating Income | -149.43% | 115.66% | |||
| Income Before Tax | -162.70% | 138.52% | |||
| Income Tax Expenses | -80.21% | 487.50% | |||
| Earnings from Continuing Operations | -164.93% | 134.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -164.93% | 134.75% | |||
| EBIT | -149.43% | 115.66% | |||
| EBITDA | -145.00% | 108.52% | |||
| EPS Basic | -164.38% | 133.39% | |||
| Normalized Basic EPS | -162.11% | 137.33% | |||
| EPS Diluted | -170.29% | 113.77% | |||
| Normalized Diluted EPS | -165.74% | 133.81% | |||
| Average Basic Shares Outstanding | 0.87% | 0.49% | |||
| Average Diluted Shares Outstanding | -4.62% | 2.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||